Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

January 2, 2024

Study Completion Date

April 24, 2024

Conditions
Non Hodgkin LymphomaHodgkin LymphomaMyelomaLymphocytic Leukemia
Interventions
DRUG

BMS-986345

"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"

DRUG

Duvelisib

"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Secura Bio, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05065866 - Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | Biotech Hunter | Biotech Hunter